- Home
- SSSS vs CHRS Comparison
SSSS vs CHRS Comparison
Compare SSSS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- CHRS
- Stock Information
- Founded
- SSSS 2010
- CHRS 2010
- Country
- SSSS United States
- CHRS United States
- Employees
- SSSS N/A
- CHRS N/A
- Industry
- SSSS Finance: Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSSS Finance
- CHRS Health Care
- Exchange
- SSSS Nasdaq
- CHRS Nasdaq
- Market Cap
- SSSS 118.1M
- CHRS 100.9M
- IPO Year
- SSSS N/A
- CHRS 2014
- Fundamental
- Price
- SSSS $4.87
- CHRS $0.78
- Analyst Decision
- SSSS Buy
- CHRS Strong Buy
- Analyst Count
- SSSS 2
- CHRS 4
- Target Price
- SSSS $6.00
- CHRS $6.13
- AVG Volume (30 Days)
- SSSS 164.2K
- CHRS 2.7M
- Earning Date
- SSSS 11-07-2024
- CHRS 11-06-2024
- Dividend Yield
- SSSS N/A
- CHRS N/A
- EPS Growth
- SSSS N/A
- CHRS N/A
- EPS
- SSSS N/A
- CHRS N/A
- Revenue
- SSSS $5,903,895.00
- CHRS $304,340,000.00
- Revenue This Year
- SSSS N/A
- CHRS $3.33
- Revenue Next Year
- SSSS $6.05
- CHRS $16.77
- P/E Ratio
- SSSS N/A
- CHRS N/A
- Revenue Growth
- SSSS 5.43
- CHRS 44.19
- 52 Week Low
- SSSS $3.32
- CHRS $0.66
- 52 Week High
- SSSS $5.44
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- SSSS 52.13
- CHRS 42.95
- Support Level
- SSSS $4.70
- CHRS $0.77
- Resistance Level
- SSSS $5.44
- CHRS $0.89
- Average True Range (ATR)
- SSSS 0.27
- CHRS 0.08
- MACD
- SSSS -0.02
- CHRS 0.02
- Stochastic Oscillator
- SSSS 29.99
- CHRS 40.24
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.